Skip to main content
. 2023 Apr 1;14(5):874–879. doi: 10.7150/jca.67189

Table 2.

Evaluation of the response at 6 and 12 months in patients treated with CIMAvax-EGF. Overall, 36.5 % and 19.8 % of all patients, maintained disease control after 6 or 12 months of vaccination, respectively.

6 months 12 months
Response No % No %
Complete response 3 2.8 3 2.8
Partial Response 10 9.4 4 3.7
Stable Disease 26 24.5 14 13.2
Progressive Disease 67 63.2 85 80.1
Global 106 100 106 100